Effective half-life, excretion and radiation exposure of 177Lu-PSMA

Simple item page
dc.contributor.authorParlak, Y
dc.contributor.authorMutevelizade, G
dc.contributor.authorSezgin, C
dc.contributor.authorGoksoy, D
dc.contributor.authorGumuser, G
dc.contributor.authorSayit, E
dc.date.accessioned2024-07-18T11:49:01Z
dc.date.available2024-07-18T11:49:01Z
dc.description.abstractThe study aims to evaluate the radiation safety conditions by detecting the patient's urine excretion rate, calculating the effective half-life, and determining the retention of Lu-177-PSMA in the body. Urine samples of patients were collected for 24 hours (6, 12, 18, and 24 hours) following the infusion, excretion rate and retention of Lu-177-PSMA in the body of patients were calculated. The measurements of dose rate were performed. Effective half-life calculated from dose rate measurements was found as 18.5 +/- 11 h within the first 24 h and 48.1 +/- 22.8 h between 24 and 72 h. Excreted activity in urine was found as 33.8 +/- 20.7, 40.4 +/- 20.3, 46.1 +/- 22.4, and 53.3 +/- 21.5% of total doses at 6, 12, 18, and 24 h after administration, respectively. External dose rates for 4 h and 24 h were 24.51 mu Sv/h, 16.14 mu Sv/h, respectively. Our results showed that Lu-177-PSMA treatment was suitable for outpatient treatment in terms of radiation safety.
dc.identifier.issn0144-8420
dc.identifier.other1742-3406
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/3696
dc.language.isoEnglish
dc.publisherOXFORD UNIV PRESS
dc.subjectRADIONUCLIDE THERAPY
dc.subjectPROSTATE-CANCER
dc.subjectTHERANOSTICS
dc.titleEffective half-life, excretion and radiation exposure of 177Lu-PSMA
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu